Back to top
more

Bionano Genomics (BNGO)

(Delayed Data from NSDQ)

$0.79 USD

0.79
560,489

+0.03 (3.57%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.78 -0.01 (-0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AbCellera Biologics Inc. (ABCL) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.

After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Bionano Genomics, Inc. (BNGO) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software

by Zacks Equity Research

QIAGEN's (QGEN) NGS interpretation software, QCI Interpret, now covers the whole exome due to additional AI capabilities.

Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.78% and 6.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?

by Zacks Equity Research

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -33.33% and 1.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics, Inc. (BNGO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Bionano Genomics, Inc. (BNGO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bionano Genomics, Inc. (BNGO) and Amarin (AMRN) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Bionano Genomics (BNGO) This Year?

by Zacks Equity Research

Here is how Bionano Genomics, Inc. (BNGO) and Aziyo Biologics, Inc. (AZYO) have performed compared to their sector so far this year.

Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bionano Genomics, Inc. (BNGO) and Exact Sciences (EXAS) have performed compared to their sector so far this year.

Bears are Losing Control Over Bionano Genomics, Inc. (BNGO), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Bionano Genomics, Inc. (BNGO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 8.33% and 7.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -10% and 7.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of 23.08% and 8.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bionano Genomics, Inc. (BNGO) Q2 Earnings Expected to Decline

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -37.50% and 5.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Bionano (BNGO) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Bionano (BNGO) stock based on the movements in the options market lately.

Bionano Genomics, Inc. (BNGO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -16.67% and 16.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics, Inc. (BNGO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -20.00% and 16.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?